Predicting nodal status using dynamic contrast-enhanced magnetic resonance imaging in patients with locally advanced breast cancer undergoing neoadjuvant chemotherapy with and without sequential trastuzumab

Archives of Surgery

Volumn 142, Issue 9, 2007, Pages 855-860

  Hsiang, David J ^a,b   Yamamoto, Maki ^a   Mehta, Rita S ^a   Su, Min Ying ^a   Baick, Choong H ^a   Lane, Karen T ^a   Butler, John A ^a  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CARBOPLATIN; CYCLOPHOSPHAMIDE; DOXORUBICIN; EPIDERMAL GROWTH FACTOR RECEPTOR 2; ESTROGEN RECEPTOR; GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR; PACLITAXEL; TRASTUZUMAB;

ADD ON THERAPY; ADJUVANT CHEMOTHERAPY; ADULT; ADVANCED CANCER; AGED; ARTICLE; AXILLARY LYMPH NODE; BREAST CANCER; CANCER CHEMOTHERAPY; CLINICAL ARTICLE; CONTRAST ENHANCEMENT; DIAGNOSTIC ACCURACY; DYNAMIC CONTRAST ENHANCED MAGNETIC RESONANCE IMAGING; FEMALE; HUMAN; LYMPH NODE DISSECTION; MASTECTOMY; NUCLEAR MAGNETIC RESONANCE IMAGING; PARTIAL MASTECTOMY; PATIENT MONITORING; PREDICTION; PRIORITY JOURNAL; RELIABILITY; RETROSPECTIVE STUDY; SENSITIVITY AND SPECIFICITY;

ADULT; AGED; ANTIBODIES, MONOCLONAL; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; AXILLA; BREAST NEOPLASMS; CARBOPLATIN; CONTRAST MEDIA; CYCLOPHOSPHAMIDE; DOXORUBICIN; FEMALE; GADOLINIUM DTPA; HUMANS; LYMPH NODE EXCISION; LYMPH NODES; LYMPHATIC METASTASIS; MAGNETIC RESONANCE IMAGING; MASTECTOMY; MASTECTOMY, SEGMENTAL; MIDDLE AGED; NEOADJUVANT THERAPY; PACLITAXEL; PREDICTIVE VALUE OF TESTS; RECEPTOR, ERBB-2; RETROSPECTIVE STUDIES; SENSITIVITY AND SPECIFICITY; TREATMENT OUTCOME;

EID: 34548778824     PISSN: 00040010     EISSN: 15383644     Source Type: Journal    
DOI: 10.1001/archsurg.142.9.855     Document Type: Article

References (28)

1. Carlson RW, Favert AM. Multidisciplinary management of locally advanced breast cancer. Breast J. 1999;5(5):303-307.
2. Mankoff DA, Dunnwald LK, Gralow JR, Ellis GK, Drucker MJ, Livingston RB. Monitoring the response of patients with locally advanced breast carcinoma to neoadjuvant chemotherapy using [technetium 99m]-sestamibi scintimammography. Cancer. 1999;85(11):2410-2423.
3. Esteva FJ, Hortobagyi GN. Advances in breast cancer therapy. Hematol Oncol Clin North Am. 1999;13(2):458-473.
4. Hortobagyi GN. Comprehensive management of locally advanced breast cancer. Cancer. 1990;66(6)(suppl):1387-1391.
5. De Lena M, Varini M, Zucali R. Multimodal treatment for locally advanced breast cancer: result of chemotherapy-radiotherapy versus chemotherapy-surgery. Cancer Clin Trials. 1981;4(3):229-236.
6. Feldman LD, Hortobagyi GN, Buzudar AU, Ames FC, Blumenschein GR. Pathological assessment of response to induction chemotherapy in breast. Cancer Res. 1986;46(5):2578-2581.
7. Helvie MA, Joynt LK, Cody RL, Pierce LJ, Adler DD, Merajve SD. Locally advanced breast carcinoma: accuracy of mammography versus clinical examination in the prediction of residual disease after chemotherapy. Radiology. 1996; 198(2):327-332.
8. Vinnicombe SJ, MacVicar AD, Guy RL, et al. Primary breast cancer: mammographic changes after neoadjuvant chemotherapy, with pathologic correlation. Radiology. 1996;198(2):333-340.
9. Conrad C, Corfitsen MT, Gyldholm N, Christiansen FL. Pre-operative MR mammography in breast cancer patients. Eur J Surg Oncol. 1999;25(2):142-145.
10. Esserman L, Hylton N, Yassa L, Barclay J, Frankel S, Sickles E. Utility of magnetic resonance imaging in the management of breast cancer: evidence for improved preoperative staging. J Clin Oncol. 1999;17(1):110-119.
11. Partridge SC, Gibbs JE, Lu Y, Esserman LJ, Sudilovsky D, Hylton NM. Accuracy of MR imaging for revealing residual breast cancer in patients who have undergone neoadjuvant chemotherapy. AJR Am J Roentgenol. 2002;179(5):1193-1199.
12. Stomper PC, Winston JS, Herman S, Klippenstein DL, Arredondo MA, Blumenson LE. Angiogenesis and dynamic MR imaging gadolinium enhancement of malignant and benign breast lesions. Breast Cancer Res Treat. 1997;45(1): 39-46.
13. Belli P, Costantini M, Malaspina C, Magistrelli A, Latorre G, Bonomo L. MRI accuracy in residual disease evaluation in breast cancer patients treated with neoadjuvant chemotherapy. Clin Radiol. 2006;61(11):946-953.
14. Stadnik TW, Everaert H, Makkat S, Sacre R, Lamote J, Bourgain C. Breast imaging: preoperative breast cancer staging: comparison of USPIO-enhanced MR imaging and 18F-fluorodeoxyglucose (FDC) positron emission tomography (PET) imaging for axillary lymph node staging-initial findings. Eur Radiol. 2006;16(10):2153-2160.
15. Memarsadeghi M, Riedl CC, Kaneider A, et al. Axillary lymph node metastases in patients with breast carcinomas: assessment with nonenhanced versus USPIO-enhanced MR imaging. Radiology. 2006;241(2):367-377.
16. Park JO, Lee SI, Song SY, et al. Measuring response in solid tumors: comparison of RECIST and WHO response criteria. Jpn J Clin Oncol. 2003;33(10): 533-537.
17. Padhani AR, Ollivier L. The RECIST (Response Evaluation Criteria in Solid Tumors) criteria: implications for diagnostic radiologists. Br J Radiol. 2001;74 (887):983-986.
18. Wolff AC, Hammond EH, Schwartz JN, et al. American Society of Clinical Oncology/ College of American Pathologists guideline recommendations for human epidermal growth factor receptor 2 testing in breast cancer. J Clin Oncol. 2007; 25(1):118-145.
19. Mehta RS, Schubbert T, Kong K, Hsiang D, Butler J, Baick C. Pathologic response (pCR) following weekly (wkly) paclitaxel (cremophor or albumin-bound) and carboplatin (TC) ± trastuzumab (H), ± bevacizumab (B) in patients (pts) with doxorubicin/cyclophosphamide-resistant (AC-Res) and AC-sensitive (AC-S) large and inflammatory breast cancer (BC) [abstract 591]. J Clin Oncol. 2007;25(18S).
20. Jones JL, Zabicki K, Christian RL, et al. A comparison of sentinel node biopsy before and after neoadjuvant chemotherapy: timing is important. AmJ Surg. 2005; 190(4):517-520.
21. Breslin TM, Cohen L, Sahin A, et al. Sentinel lymph node biopsy is accurate after neoadjuvant chemotherapy for breast cancer. J Clin Oncol. 2000;18(20):3480-3486.
22. Nason KS, Anderson BO, Byrd DR, et al. Increased false negative sentinel node biopsy rates after preoperative chemotherapy for invasive breast carcinoma. Cancer. 2000;89(11):2187-2194.
23. Julian TB, Patel N, Dusi D, et al. Sentinel lymph node biopsy after neoadjuvant chemotherapy for breast cancer. Am J Surg. 2001;182(4):407-410.
24. Haid A, Tausch C, Lang A, et al. Is sentinel lymph node biopsy reliable and indicated after preoperative chemotherapy in patients with breast carcinoma? Cancer. 2001;92(5):1080-1084.
25. Mamounas EP, Brown A, Anderson S, et al. Sentinel node biopsy after neoadjuvant chemotherapy in breast cancer: results from National Surgical Adjuvant Breast and Bowel Project Protocol B-27 (published correction appeared in J Clin Oncol. 2005;23(21):4808). J Clin Oncol. 2005;23(12):2694-2702.
26. Shin JH, Choi HY, Moon BI, Sung SH. In vitro sonographic evaluation of sentinel lymph nodes for detecting metastasis in breast cancer: comparison with histopathologic results. J Ultrasound Med. 2004;23(7):923-928.
27. Close LG, Merkel M, Vuitch MF, Reisch J, Schaefer SD. Computed tomographic evaluation of regional lymph node involvement in cancer of the oral cavity and oropharynx. Head Neck. 1989;11(4):309-317.
28. Shetty MK, Carpenter WS. Sonographic evaluation of isolated abnormal axillary lymph nodes identified on mammograms. J Ultrasound Med. 2004;23(1): 63-71.